Clinical trials: Nutritional Evaluation
Diabetes Mellitus
Evaluation of GLUCOFACTS® Deluxe Diabetes Management System
The purpose of this study is to evaluate a Diabetes management program in the hands of potential users, both health care professionals and lay persons.
- Trial name
- NCT00892151
- Testing
- GLUCOFACTS® Deluxe
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Ascensia Diabetes Care
Myelodysplastic Syndrome, Thalassemia
This Study Will Evaluate Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndromes (MDS), Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload.
This study will evaluate the efficacy and safety of deferasirox in patients with MDS, thalassemia and rare anemia patients with transfusion iron overload.
- Trial name
- NCT01250951
- Testing
- Deferasirox
- Where
- 2 sites in Russia
- Volunteers
- 111 people
- Sponsor
- Novartis Pharmaceuticals
Amyotrophic Lateral Sclerosis, Fasciculation
Study to Evaluate Safety & Efficacy of FLX-787-ODT to Treat Fasciculations in Tongue and Appendicular Muscle in Adult Subjects With ALS
The FLX-787-107 study will determine how well FLX-787-ODT works to reduce fasciculations in patients with Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- NCT03334786
- Testing
- FLX-787-ODT
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Flex Pharma, Inc.
Fluid and Electrolyte Imbalance, Overhydration
Contributing Factors to Local Bioimpedance Spectroscopy
This is an exploratory interventional study. The aim of the investigation is to identify and quantify contributing factors to local bioimpedance spectroscopy (BIS) measured by a wearable sensor patch, particularly the effect of…
- Conditions
- Fluid and Electrolyte Imbalance, Overhydration, Edema
- Trial name
- COBI (NCT06003205)
- Testing
- Wearable bioimpedance sensor
- Where
- Norway
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Mode Sensors AS
Type 2 Diabetes Mellitus
Initial Combination With Pioglitazone Study (0431-064)
A clinical study to evaluate the safety and efficacy of the initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes mellitus not on treatment with insulin or oral antihyperglycemic therapy.
- Trial name
- NCT00397631
- Testing
- sitagliptin 100 mg q.d./pioglitazone 30 mg q.d
- Volunteers
- 520 people
- Sponsor
- Merck Sharp & Dohme LLC
Dyslipidemia
A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides
This Phase 2 proof-of-concept study will assess the lipid regulating efficacy and safety of ETC-1002 in subjects with hypercholesterolemia and either normal or elevated triglycerides.
- Trial name
- NCT01262638
- Testing
- ETC-1002
- Where
- 11 sites in United States
- Volunteers
- 177 people
- Sponsor
- Esperion Therapeutics, Inc.
Dyslipidemia
A Study to Evaluate MK1903 in Patients With Dyslipidemia (MK1903-004)
This study will evaluate the lipid-modifying effect and tolerability of MK1903 when compared to placebo in patients with dyslipidemia who are not on a statin or other lipid-modifying therapy.
- Trial name
- NCT00847197
- Testing
- MK1903
- Volunteers
- 191 people
- Sponsor
- Merck Sharp & Dohme LLC
Dyslipidemia
Evaluation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TA-8995 After Multiple Doses in Healthy Subjects
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of TA-8995 after multiple doses in healthy adult male subjects
- Trial name
- NCT01879020
- Testing
- TA-8995
- Where
- Germany
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Tanabe Pharma Corporation
Obesity
A Controlled-Study on the Effect of a Combination of Fenofibrate and Metformin on Weight Loss and Weight Loss-Maintenance, in Obese Patients.
To investigate the effect on body weight of a combination fenofibrate and metformin on top of a moderate balanced calorie-deficit diet.
- Trial name
- NCT00349635
- Testing
- Metformin and Metformin + Fenofibrate
- Where
- 3 sites in Finland
- Volunteers
- 148 people
- Sponsor
- Solvay Pharmaceuticals
Diabetes Mellitus, Type 2
Assessment of the Skin-concentration of Vildagliptin 50 mg Every 12 Hours for 10 Days in Healthy Subjects and Patients With Type 2 Diabetes
This study will look at the skin accumulation of vildagliptin and its two major metabolites, LAY151 and LAF237-O-Glucuronide, after vildagliptin 50 mg given orally twice a day for 10 days in both healthy volunteers and patients…
- Trial name
- NCT00633997
- Testing
- Vildagliptin
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Novartis
Amyotrophic Lateral Sclerosis (ALS)
A Study to Evaluate the Performance of a Diagnostic Test in ALS
Prospective multicenter study of subjects who were recently diagnosed with amyotrophic lateral sclerosis (ALS) or another neurodegenerative disease (including spinal cord diseases, muscle diseases and neurological diseases such…
- Trial name
- NCT02759913
- Testing
- Lumbar puncture
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Iron Horse Diagnostics, Inc.
End Stage Kidney Disease (ESKD)
A Phase 1b Study to Evaluate the PK of CSL300 (Clazakizumab) in Chinese Subjects With End Stage Kidney Disease (ESKD)
This is a phase 1b, partial-blind (Sponsor unblinded), randomized, multicenter, placebo-controlled study. The primary objective of this study is to evaluate the pharmacokinetics (PK) of CSL300 after single and multiple doses in…
- Trial name
- NCT07619820
- Testing
- CSL300
- Where
- China
- Volunteers
- 24 people
- Sponsor
- CSL Behring
Inflammation and Fibrosis, Diabetes
Safety and Tolerability of PBI-4050 and Its Effects on the Biomarkers in Subjects With Alström Syndrome
This is a Phase 2, single-centre, single-arm, open-label study of the safety, tolerability, and effects on biomarkers of PBI-4050 in subjects with Alström syndrome for a treatment duration of 24 weeks.
- Trial name
- NCT02739217
- Testing
- PBI-4050
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- Liminal BioSciences Ltd.
Diabetes Mellitus, Type 1
Diabetes AutoimmunitY Withdrawn in Established Patients (DAY)
The study is a prospective, randomized, double-blind, placebo-controlled, multicenter trial in subjects with established T1D.
- Trial name
- DAY (NCT03794960)
- Testing
- TOL-3021
- Sponsor
- Tolerion, Inc.
Cardiovascular Disease
Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding Study
Evaluate the effect of olpasiran administered subcutaneously (SC) compared with placebo, on percent change from baseline in lipoprotein(a) (Lp[a]).
- Trial name
- NCT04270760
- Testing
- Olpasiran
- Where
- 36 sites in United States, Australia and 5 more
- Volunteers
- 281 people
- Sponsor
- Amgen
Obesity, Diabetes Mellitus, Type 2
Study of Subcutaneously Administered ENT-03 for the Treatment of Obesity and Diabetes
Single center, single-dose, randomized, placebo-controlled, dose-escalating study to evaluate, safety, tolerability, pharmacokinetics, and pharmacodynamics of escalating doses of ENT-03S in obese but otherwise healthy subjects…
- Trial name
- NCT05925920
- Testing
- ENT-03
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Metabolics Pharma
Diabetes Mellitus, Type 2
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Doses of JNJ-38431055, Sitagliptin, and Co-administration of JNJ-38431055 and Sitagliptin
This study will assess the safety, tolerability, pharmacokinetics (explores what the body does to the drug), and pharmacodynamics (explores what a drug does to the body) of single doses of JNJ-38431055, sitagliptin, and…
- Trial name
- NCT01054118
- Testing
- JNJ-38431055, Sitagliptin 100 mg, JNJ-38431055 + Sitagliptin 100 mg
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Fabry Disease
A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease
Study to evaluate the safety, tolerability, and pharmacodynamics of migalastat hydrochloride (HCl) (migalastat) and how migalastat works in participants with Fabry disease.
- Trial name
- NCT00283959
- Testing
- migalastat HCl
- Where
- 2 sites in Australia, Brazil
- Volunteers
- 4 people
- Sponsor
- Amicus Therapeutics
Obesity
A Study to Evaluate the Safety, Tolerability, and Weight Loss Efficacy of K-757 Alone and in Combination With K-833
This is a study to evaluate the safety and efficacy of K-757 alone and in combination with K-833 versus placebo in participants who are obese.
- Trial name
- NCT06019559
- Testing
- K-757 120 mg BID and K-833 100 mg BID
- Where
- 22 sites in United States
- Volunteers
- 155 people
- Sponsor
- TriGemX Bio, Inc.
Hyperlipidemia
Efficacy and Safety of Imported Probucol to Treat Hyperlipidemia
The purpose of this study is to evaluate the efficacy and safety of imported Probucol in hyperlipidemia patients.
- Trial name
- NCT01349010
- Testing
- Probucol
- Where
- China
- Volunteers
- 264 people
- Sponsor
- Otsuka Beijing Research Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.